Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis.

As many as 10% of infants with Down syndrome (DS) present with transient myeloproliferative disorder (TMD) at or shortly after birth. TMD is characterized by an abundance of blasts within the peripheral blood and liver, and notably undergoes spontaneous remission in the majority of cases. TMD may be a precursor to acute megakaryoblastic leukemia (AMKL), with an estimated 30% of TMD patients developing AMKL within 3 years. We recently reported that mutations in the transcription factor GATA1 are associated with DS-AMKL. To determine whether the acquisition of GATA1 mutations is a late event restricted to acute leukemia, we analyzed GATA1 in DNA from TMD patients. Here we report that GATA1 is mutated in the TMD blasts from every infant examined. These results demonstrate that GATA1 is likely to play a critical role in the etiology of TMD, and mutagenesis of GATA1 represents a very early event in DS myeloid leukemogenesis.

[1]  J. Downing,et al.  Acute leukemia: a pediatric perspective. , 2002, Cancer cell.

[2]  S. Orkin,et al.  X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1 interaction. , 2002, Blood.

[3]  M. L. Beau,et al.  Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome , 2002, Nature Genetics.

[4]  J. Hilden,et al.  Transient myeloproliferative disorder, a disorder with too few data and many unanswered questions: does it contain an important piece of the puzzle to understanding hematopoiesis and acute myelogenous leukemia? , 2002, Journal of pediatric hematology/oncology.

[5]  Y. Ravindranath,et al.  Down syndrome and the transient myeloproliferative disorder: why is it transient? , 2002, Journal of pediatric hematology/oncology.

[6]  M. Crossley,et al.  X-linked thrombocytopenia caused by a novel mutation of GATA-1. , 2001, Blood.

[7]  C Thys,et al.  Platelet characteristics in patients with X-linked macrothrombocytopenia because of a novel GATA1 mutation. , 2001, Blood.

[8]  B. Lange.  The Management of Neoplastic Disorders of Haematopoeisis in Children with Down's Syndrome , 2000, British journal of haematology.

[9]  S. Orkin,et al.  Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1 , 2000, Nature Genetics.

[10]  A. Zipursky,et al.  The role of p53 in megakaryocyte differentiation and the megakaryocytic leukemias of Down syndrome. , 2000, Cancer genetics and cytogenetics.